Business Wire

Gilead Sciences and Goldfinch Bio Announce Strategic Collaboration to Develop Novel Therapies for Kidney Disease

Del

Gilead Sciences, Inc. (Nasdaq: GILD) and Goldfinch Bio, Inc., a biotechnology company focused on developing precision therapies for patients with kidney diseases, today announced a strategic collaboration to discover, develop and commercialize a pipeline of innovative therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190508005070/en/

Under the multi-year collaboration, Gilead has exclusive options to license worldwide rights to certain products directed toward targets emerging from Goldfinch’s proprietary Kidney Genome Atlas™ (KGA), a comprehensive registry of patients with kidney diseases integrating genomic, transcriptomic and proteomic data with patient clinical profiles. In addition, Goldfinch will apply its biology platform of human induced pluripotent stem cell-derived kidney cells and kidney organoids to validate targets and support discovery and development of products to which Gilead will have exclusive option rights.

Through sequencing the DNA of a large cohort of diabetic patients with and without kidney disease, Goldfinch will expand the scope of the KGA beyond orphan kidney diseases to include DKD. In addition to target identification and validation, Goldfinch will lead discovery and development activities prior to exercise of exclusive option rights by Gilead, at which time Gilead will be responsible for the development and commercialization of optioned products. Goldfinch retains the option to lead development and co-promote optioned products directed to specific kidney disease targets. The collaboration does not include Goldfinch’s existing programs, GFB-887 and GFB-024, for which Goldfinch will retain all rights.

“We are excited to partner with Gilead Sciences, a biopharmaceutical company known for its science-driven innovation and productivity,” said Tony Johnson, MD, Goldfinch’s President and Chief Executive Officer. “There is significant unmet need to improve health outcomes for patients with kidney diseases. This partnership will leverage Goldfinch’s KGA platform to identify new therapeutic targets and Gilead’s proven track record of efficiently advancing life-saving therapies for patients.”

“Goldfinch has established unique genetic and biology platforms that will allow for the identification and validation of novel targets for kidney disease and for the discovery and development of novel compounds,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development at Gilead Sciences. “We look forward to partnering with our research collaborators at Goldfinch, as we seek to advance novel treatment options for people living with DKD and other serious kidney diseases.”

Under the terms of the agreement, Goldfinch will receive $55 million in upfront payments, which includes a $5 million equity investment, and an additional $54 million to support the development of the KGA platform for DKD. Goldfinch is also eligible to receive up to $1.95 billion in potential payments for the first five collaboration programs based on the successful achievement of research, development, regulatory and commercial milestones, and tiered royalties on sales of potential products originating from the collaboration. Additionally, Goldfinch retains the option to equally share in U.S. profits for certain optioned products in certain pre-defined kidney indications. Development costs for profit share products will be shared among the two parties in a manner commensurate with product rights.

About Diabetic Kidney Disease

Diabetic kidney disease (DKD) develops in approximately 30-40 percent of patients who have diabetes and is a leading cause of end-stage kidney disease, cardiovascular disease and early mortality worldwide. Despite current therapies, the number of people with DKD continues to increase, highlighting the need for additional treatments that preserve kidney function.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.

About Goldfinch Bio

Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for patients with kidney diseases. Just as the goldfinch has long been a symbol of healing and renewal and was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for patients with kidney diseases. Goldfinch was launched in 2016 by Third Rock Ventures, and is headquartered in Cambridge, Mass. For more information, please visit www.goldfinchbio.com.

Gilead Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration, and Gilead may fail to discover, develop and commercialize any product candidates for the treatment of diabetic kidney disease and other kidney diseases. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Contact information

Gilead Contacts:

Sung Lee, Investors
(650) 524-7792

Nathan Kaiser, Media
(650) 522-1853

Goldfinch Contacts:

Michael Broxson, Investors
617-337-4200
mbroxson@goldfinchbio.com

Gina Nugent, Media
617-460-3579
gina@theyatesnetwork.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

GLIDE and eBay Present the 20th Annual Auction for Power Lunch with Warren Buffett, May 26 – May 3120.5.2019 11:00:00 CESTPressemelding

GLIDE is pleased to announce the annual eBay for Charity Auction for Power Lunch with Warren Buffett, which will begin at 7:30 pm PDT on Sunday, May 26 and end at 7:30 pm PDT on Friday, May 31, 2019. This year marks the 20th anniversary of the legendary auction, which to date has provided nearly $30 million to support GLIDE’s comprehensive suite of social services that help San Francisco’s most vulnerable residents overcome hunger, poverty, homelessness and health challenges as well as social isolation and marginalization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005017/en/ “It makes a difference, and it translates into human beings finding that there is hope in life and that something better is there,” Mr. Buffett said recently about the money raised for GLIDE over the past 20 years. The annual Power Lunch with Warren Buffett is made possible through the support of eBay for Charity. The winning bidder and up to

PEI-Genesis Promotes Peter Austin to General Manager North America and Corporate Senior Vice President20.5.2019 11:00:00 CESTPressemelding

PEI-Genesis, the world’s fastest assembler of precision connectors, has promoted Peter Austin to General Manager North America and Corporate Senior Vice President, effective immediately. He will continue to report directly to Steven Fisher, PEI-Genesis Chairman and CEO. “Since joining PEI-Genesis in 2016, Peter has proven to be a valuable leader and an unparalleled strategic thinker in working to move the business forward,” said Fisher. “With his decades of experience in the electronics industry, his innovative thinking, and his ability to lead teams across North America, we have many accomplishments to tout, all directly related to his work.” In addition to his current responsibilities, in his new General Manager role, Austin will have responsibility for all operations in North America, including the company’s production facilities in South Bend, IN, Chandler, AZ, and Nogales, Mexico. He’ll also have leadership of the company’s North American Sales units. “My tenure at PEI has been a

Enlighted Expands IoT Platform Lighting Control Capabilities20.5.2019 10:00:00 CESTPressemelding

Enlighted, the leading provider of Internet of Things (IoT) solutions for commercial buildings and healthcare facilities, today announced new lighting control capabilities have been added to its award-winning building IoT Platform. These include advanced tunable white lighting control, daylight harvesting group capabilities, and a two-wire interface for the company’s powerful sensors. Together these new advancements improve the health and well-being of building occupants, improve lighting aesthetics, simplify fixture integration and reduce costs. Advanced Tunable White Lighting Control Enlighted sensors go beyond the automated circadian rhythm capabilities typically found in today’s tunable white solutions and now provide user-level control of color temperature to desired levels. The color temperature can be automatically aligned with the astronomical clock or directly tuned according to specific user needs. Occupants can tailor their environment, improve productivity and comfort, and

ams, Ibeo and ZF Partner to Deliver Industry-First Solid-State LiDAR Systems for the Automotive Industry20.5.2019 09:36:00 CESTPressemelding

ams (SIX: AMS), a leading worldwide supplier of high performance sensor solutions, announces today that it has signed an agreement to team with Ibeo Automotive Systems GmbH, the German specialist for automotive LiDAR sensor technology, and ZF Friedrichshafen AG, one of the leading technology companies for mobility worldwide to advance solid-state LiDAR technology for use in autonomous driving and other applications. The three companies will partner on joint R&D efforts to ensure that this exciting technology can be quickly and safely adopted by 2021. LiDAR is an optical sensing technology that measures distance and direction of the surrounding objects by illuminating them with a laser beam and detecting the reflection of the object. Its unique range and resolution properties complement radar and camera solutions to enable the ‘Holy Grail’ of the self-driving car industry – SAE level 5* or fully autonomous driving. ams will provide automotive-grade VCSEL (Vertical Cavity Surface Emittin

Personalis, Inc. to Present at Advances in Immuno-Oncology Congress UK 201920.5.2019 07:05:00 CESTPressemelding

Personalis, Inc., a leader in advanced genomics for cancer, today announced that the company will present at Advances in Immuno-Oncology Congress UK 2019 in London on May 21st at 11:00 AM BST. The presentation, entitled “Advancing Precision Oncology Biomarker Discovery with a Multi-dimensional Immunogenomics Platform,” will introduce Personalis’ new universal cancer immunogenomics platform, ImmunoID NeXT™. In addition to an overview, the presentation will introduce preliminary data from an ongoing study in which this platform is being used to evaluate IO-related biomarkers and potential tumor escape mechanisms in a cohort of melanoma patients treated with anti-PD-1 therapy. ImmunoID NeXT™ is the first platform to provide comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one. This maximizes the

New Study Evaluates Ability of Masimo SpHb® (Noninvasive Hemoglobin) to Estimate Timing for Invasive Measurement to Detect Anemia During Surgery20.5.2019 07:00:00 CESTPressemelding

Masimo (NASDAQ: MASI) announced today the results of a study published in BMC Anesthesiology in which clinicians at Peking Union Medical College in Beijing evaluated the ability of noninvasive and continuous hemoglobin monitoring with Masimo SpHb® to help clincians estimate when to conduct invasive hemoglobin measurement to detect possible anemia in patients undergoing spine or cytoreductive surgery.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005244/en/ Masimo Radical-7® with SpHb® (Photo: Business Wire) Noting that because of the “invasive, time-consuming and intermittent” nature of invasive blood sampling, clincians often forgo these “objective indications” when making transfusion decisions during surgery, Dr. Tang and colleagues sought to determine whether noninvasive, continuous hemoglobin monitoring could aid clinicians in estimating when it might be appropriate to perform an invasive measurement. They enroll